A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet need for new treatment options for patients that are ineligible for, or resistant to these therapies. BH3 mimetics, drugs that mimic the act...

Full description

Bibliographic Details
Main Authors: Chiara R. Dart, Nabanita Mukherjee, Carol M. Amato, Anabel Goulding, Morgan MacBeth, Robert Van Gulick, Kasey L. Couts, James R. Lambert, David A. Norris, William A. Robinson, Yiqun G. Shellman
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
melanoma
azacitidine
BH3 mimetic
Online Access:https://www.mdpi.com/1424-8247/14/8/749

Internet

https://www.mdpi.com/1424-8247/14/8/749

Similar Items